Lexaria Bioscience financials
$3.13−2.95%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Aug 31 | FY24 Aug 31 | FY23 Aug 31 | FY22 Aug 31 | FY21 Aug 31 |
|---|---|---|---|---|---|
| Revenue | $705.9K | $464.3K | $226.2K | $255.4K | $722.7K |
| Gross profit | $703.2K | $459.5K | $194.7K | $183.6K | $547.4K |
| Gross margin | 99.6% | 99.0% | 86.1% | 71.9% | 75.7% |
| Operating income | -$11.9M | -$5.8M | -$6.5M | -$6.6M | -$5.7M |
| Net income | -$11.9M | -$5.8M | -$6.7M | -$7.3M | -$4.0M |
| Net margin | −1686.0% | −1248.2% | −2946.4% | −2846.3% | −557.2% |
| Diluted EPS | $-9.90 | $-7.05 | $-15.15 | $-18.60 | $-13.80 |
| EBITDA | -$11.8M | -$5.7M | -$6.4M | -$6.5M | -$5.5M |
| Operating cash flow | -$10.5M | -$5.0M | -$5.9M | -$4.9M | -$4.0M |
| Free cash flow | -$10.5M | -$5.0M | -$5.9M | -$4.9M | — |
| Diluted shares | 1.2M | 0.8M | 0.4M | 0.4M | 0.3M |
Balance sheet
| Period end | Aug 31 | Aug 31 | Aug 31 | Aug 31 | Aug 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $1.8M | $6.5M | $1.4M | $5.8M | $10.9M |
| Short-term investments | $165.4K | $55.8K | $125.6K | $347.3K | $833.8K |
| Total debt | $0.00 | $0.00 | $164.0K | $50.0K | $97.3K |
| Total assets | $4.2M | $8.9M | $3.1M | $7.8M | $13.3M |
| Total liabilities | $1.6M | $1.2M | $403.9K | $201.4K | $203.3K |
| Shareholders' equity | $2.6M | $7.7M | $2.7M | $7.6M | $13.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology